LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis

Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. The expression of HULC and miR-372-3p in osteosa...

Full description

Saved in:
Bibliographic Details
Published inMolecular medicine (Cambridge, Mass.) Vol. 26; no. 1; pp. 26 - 12
Main Authors Li, Yong, Liu, Jing-Jing, Zhou, Jia-Hui, Chen, Rui, Cen, Chao-Qun
Format Journal Article
LanguageEnglish
Published England BioMed Central 18.03.2020
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.
AbstractList Abstract Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. Methods The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Results Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3′-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Conclusion Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.
Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms.BACKGROUNDOsteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms.The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay.METHODSThe expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay.Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion.RESULTSOur results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion.Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.CONCLUSIONOur study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.
Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. Methods The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Results Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3′-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Conclusion Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.
Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.
ArticleNumber 26
Author Cen, Chao-Qun
Li, Yong
Liu, Jing-Jing
Zhou, Jia-Hui
Chen, Rui
Author_xml – sequence: 1
  givenname: Yong
  surname: Li
  fullname: Li, Yong
– sequence: 2
  givenname: Jing-Jing
  surname: Liu
  fullname: Liu, Jing-Jing
– sequence: 3
  givenname: Jia-Hui
  surname: Zhou
  fullname: Zhou, Jia-Hui
– sequence: 4
  givenname: Rui
  surname: Chen
  fullname: Chen, Rui
– sequence: 5
  givenname: Chao-Qun
  surname: Cen
  fullname: Cen, Chao-Qun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32188407$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhiNURD_gD3BAkbhwCfVHHMcXpHYF3UoLSBU9WxN7knqVxIudIPrvcXZbRHvgMLI17zOvRjNzmh2NfsQse0vJR0rr6jxSQhgp9kGoEIV4kZ1QweqCV6I-Sn8iqyIJ9Dg7jXGbaCpK8So75ozWdUnkSdZuRnPz7SJf325WuRvtbDDm0x3mu-C7gDE6P-a-zX2c0EcIxg-QN_d5wG7uYXJjt6cHd1NwyQq-O19_vbqkeXTdCH2_6PDbxdfZyxb6iG8e3rPs9svnH6t1sfl-db262BRGKDkVijWMgq2RKtVK2hphQclW8EZxk0RpOHC0KQsNSmKrCplAC6ZhjBFD-Fl2ffC1HrZ6F9wA4V57cHqf8KHTECZnetTUyBYZsZbIsgTkUCloeVuikU0FFpLXp4PXbm4GtAbHKUD_xPSpMro73flfWpKaCsWSwYcHg-B_zhgnPbhosO9hRD9HzbhUhKeVLOj7Z-jWzyFNMFGirBRXvJKJevdvR39beVxnAuoDYIKPMWCrjZvSlvzSoOs1JXq5HH24HL2P5XK0SKXsWemj-3-K_gDbOMXV
CitedBy_id crossref_primary_10_1016_j_omtn_2020_11_009
crossref_primary_10_3389_fcell_2022_773038
crossref_primary_10_3390_medicines7040019
crossref_primary_10_1016_j_compbiomed_2024_108403
crossref_primary_10_1016_j_biopha_2024_116924
crossref_primary_10_1093_carcin_bgac065
crossref_primary_10_1016_j_bbadis_2024_167357
crossref_primary_10_1111_cas_15989
crossref_primary_10_1038_s41598_020_80817_w
crossref_primary_10_1515_biol_2021_0058
crossref_primary_10_1152_ajpcell_00296_2022
crossref_primary_10_15252_msb_20209810
crossref_primary_10_3727_096504020X15982623243955
crossref_primary_10_1016_j_cellsig_2023_110772
crossref_primary_10_1016_j_heliyon_2023_e15991
crossref_primary_10_3390_ijms24108993
crossref_primary_10_3390_cells11081267
crossref_primary_10_1186_s12929_024_01049_y
crossref_primary_10_3389_fimmu_2022_1025532
crossref_primary_10_1155_2022_4342755
crossref_primary_10_1016_j_labinv_2022_100054
crossref_primary_10_3389_fgene_2022_1028477
crossref_primary_10_3389_fimmu_2021_763323
crossref_primary_10_3389_fgene_2022_1022155
crossref_primary_10_3390_ph15070811
Cites_doi 10.1016/j.mam.2014.05.001
10.1016/j.cell.2005.06.036
10.1016/j.ejca.2012.10.018
10.1200/JCO.2014.59.4895
10.1038/bjc.2013.607
10.1038/nsmb0705-569
10.1161/CIRCRESAHA.117.311802
10.1038/s12276-018-0082-5
10.1016/j.bbagrm.2014.08.012
10.1093/emboj/cdg228
10.1196/annals.1294.016
10.1186/s12943-016-0530-6
10.1200/JCO.20.3.776
10.1080/14737140.2018.1413939
10.1016/S0092-8674(04)00045-5
10.2147/OTT.S149889
10.1016/j.ctrv.2013.11.006
10.3390/ijms17101712
10.1093/nar/gkq285
10.1007/s00018-016-2174-5
10.1111/jcmm.12956
10.1159/000479205
10.1002/cam4.1026
10.1517/17530050802608496
10.18632/oncotarget.4154
10.1186/1476-4598-13-92
10.3892/mmr.2014.2546
10.1158/0008-5472.CAN-11-2001
10.1155/2014/970607
10.4161/auto.8.2.18940
10.1016/j.cell.2011.07.014
10.1002/jcb.26273
10.1016/j.bbrc.2019.10.105
10.1146/annurev.cellbio.19.011102.111135
ContentType Journal Article
Copyright 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The Author(s) 2020
Copyright_xml – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s10020-020-00155-5
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1528-3658
EndPage 12
ExternalDocumentID oai_doaj_org_article_1c7fe20dd0744ae3a69af3f4ec7b6ada
PMC7081592
32188407
10_1186_s10020_020_00155_5
Genre Journal Article
GeographicLocations United States--US
China
Japan
GeographicLocations_xml – name: China
– name: United States--US
– name: Japan
GroupedDBID ---
-ET
0R~
123
29M
2WC
36B
5RE
5VS
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFO
ACMJI
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IH2
IHR
ISR
ITC
KQ8
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
RBZ
RNS
ROL
RPM
RSV
SDH
SJN
SOJ
SV3
TR2
UKHRP
WOQ
ACRMQ
C24
M~E
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c597t-92b21ad8e199f71fc5da97f53b93c92b7c3a3ed5daabe70d66e25edacb2220c03
IEDL.DBID 7X7
ISSN 1076-1551
1528-3658
IngestDate Wed Aug 27 01:30:35 EDT 2025
Thu Aug 21 14:21:38 EDT 2025
Fri Jul 11 04:39:39 EDT 2025
Mon Jun 30 13:41:16 EDT 2025
Thu Jan 02 22:58:17 EST 2025
Tue Jul 01 01:25:21 EDT 2025
Thu Apr 24 23:01:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ceRNA
HMGB1
Osteosarcoma
HULC
miR-372-3p
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-92b21ad8e199f71fc5da97f53b93c92b7c3a3ed5daabe70d66e25edacb2220c03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2546939367?pq-origsite=%requestingapplication%
PMID 32188407
PQID 2546939367
PQPubID 5066171
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_1c7fe20dd0744ae3a69af3f4ec7b6ada
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7081592
proquest_miscellaneous_2379031542
proquest_journals_2546939367
pubmed_primary_32188407
crossref_citationtrail_10_1186_s10020_020_00155_5
crossref_primary_10_1186_s10020_020_00155_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-03-18
PublicationDateYYYYMMDD 2020-03-18
PublicationDate_xml – month: 03
  year: 2020
  text: 2020-03-18
  day: 18
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
– name: London
PublicationTitle Molecular medicine (Cambridge, Mass.)
PublicationTitleAlternate Mol Med
PublicationYear 2020
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References MJ Wheelock (155_CR32) 2003; 19
Y Wang (155_CR31) 2018; 50
DJ Harrison (155_CR10) 2018; 18
Z Li (155_CR20) 2017; 42
RB Hazan (155_CR11) 2004; 1014
155_CR14
155_CR36
Y Wang (155_CR30) 2017; 10
J Huang (155_CR13) 2012; 72
155_CR22
J Wang (155_CR28) 2010; 38
A Luetke (155_CR23) 2014; 40
D Kong (155_CR18) 2018; 119
J Huang (155_CR12) 2012; 8
C Catalanotto (155_CR6) 2016; 17
T Sallam (155_CR24) 2018; 122
SS Bielack (155_CR5) 2002; 20
R Kang (155_CR15) 2014; 40
G Christofori (155_CR7) 2003; 22
T Kinoshita (155_CR16) 2013; 109
N Bartonicek (155_CR4) 2016; 15
SU Schmitz (155_CR26) 2016; 73
CM Croce (155_CR8) 2005; 122
155_CR9
Guodong Yang (155_CR35) 2014; 1839
SY Xu (155_CR34) 2018; 22
Q Wang (155_CR29) 2017; 6
DAJIANG WU (155_CR33) 2014; 10
DP Bartel (155_CR3) 2004; 116
155_CR27
AM Ardekani (155_CR1) 2010; 2
L Salmena (155_CR25) 2011; 146
B Bartel (155_CR2) 2005; 12
W-C Liang (155_CR21) 2015; 6
C Kong (155_CR17) 2009; 3
HE Lee (155_CR19) 2013; 49
References_xml – volume: 40
  start-page: 1
  year: 2014
  ident: 155_CR15
  publication-title: Mol Asp Med
  doi: 10.1016/j.mam.2014.05.001
– volume: 122
  start-page: 6
  issue: 1
  year: 2005
  ident: 155_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2005.06.036
– volume: 49
  start-page: 1448
  issue: 6
  year: 2013
  ident: 155_CR19
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2012.10.018
– ident: 155_CR14
  doi: 10.1200/JCO.2014.59.4895
– volume: 109
  start-page: 2636
  issue: 10
  year: 2013
  ident: 155_CR16
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.607
– volume: 12
  start-page: 569
  issue: 7
  year: 2005
  ident: 155_CR2
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb0705-569
– volume: 122
  start-page: 155
  issue: 1
  year: 2018
  ident: 155_CR24
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.117.311802
– volume: 50
  start-page: 57
  issue: 5
  year: 2018
  ident: 155_CR31
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-018-0082-5
– volume: 1839
  start-page: 1097
  issue: 11
  year: 2014
  ident: 155_CR35
  publication-title: Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
  doi: 10.1016/j.bbagrm.2014.08.012
– volume: 22
  start-page: 2318
  issue: 10
  year: 2003
  ident: 155_CR7
  publication-title: EMBO J
  doi: 10.1093/emboj/cdg228
– volume: 1014
  start-page: 155
  year: 2004
  ident: 155_CR11
  publication-title: Ann N Y Acad Sci
  doi: 10.1196/annals.1294.016
– volume: 15
  start-page: 43
  issue: 1
  year: 2016
  ident: 155_CR4
  publication-title: Mol Cancer
  doi: 10.1186/s12943-016-0530-6
– volume: 20
  start-page: 776
  issue: 3
  year: 2002
  ident: 155_CR5
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.3.776
– volume: 18
  start-page: 39
  issue: 1
  year: 2018
  ident: 155_CR10
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1080/14737140.2018.1413939
– volume: 116
  start-page: 281
  issue: 2
  year: 2004
  ident: 155_CR3
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
– volume: 10
  start-page: 5355
  year: 2017
  ident: 155_CR30
  publication-title: Oncotargets Ther
  doi: 10.2147/OTT.S149889
– volume: 22
  start-page: 62
  issue: 1
  year: 2018
  ident: 155_CR34
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 40
  start-page: 523
  issue: 4
  year: 2014
  ident: 155_CR23
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2013.11.006
– volume: 17
  start-page: 1712
  issue: 10
  year: 2016
  ident: 155_CR6
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms17101712
– volume: 38
  start-page: 5366
  issue: 16
  year: 2010
  ident: 155_CR28
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkq285
– volume: 73
  start-page: 2491
  issue: 13
  year: 2016
  ident: 155_CR26
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-016-2174-5
– ident: 155_CR36
  doi: 10.1111/jcmm.12956
– volume: 42
  start-page: 1407
  year: 2017
  ident: 155_CR20
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000479205
– volume: 6
  start-page: 1323
  issue: 6
  year: 2017
  ident: 155_CR29
  publication-title: Cancer Med
  doi: 10.1002/cam4.1026
– volume: 3
  start-page: 13
  issue: 1
  year: 2009
  ident: 155_CR17
  publication-title: Expert Opin Med Diagn
  doi: 10.1517/17530050802608496
– volume: 6
  start-page: 22513
  issue: 26
  year: 2015
  ident: 155_CR21
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4154
– ident: 155_CR22
  doi: 10.1186/1476-4598-13-92
– volume: 10
  start-page: 2415
  issue: 5
  year: 2014
  ident: 155_CR33
  publication-title: Molecular Medicine Reports
  doi: 10.3892/mmr.2014.2546
– volume: 72
  start-page: 230
  issue: 1
  year: 2012
  ident: 155_CR13
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-2001
– ident: 155_CR27
  doi: 10.1155/2014/970607
– volume: 8
  start-page: 275
  issue: 2
  year: 2012
  ident: 155_CR12
  publication-title: Autophagy
  doi: 10.4161/auto.8.2.18940
– volume: 146
  start-page: 353
  issue: 3
  year: 2011
  ident: 155_CR25
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.014
– volume: 119
  start-page: 1050
  issue: 1
  year: 2018
  ident: 155_CR18
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.26273
– ident: 155_CR9
  doi: 10.1016/j.bbrc.2019.10.105
– volume: 2
  start-page: 161
  issue: 4
  year: 2010
  ident: 155_CR1
  publication-title: Avicenna J Med Biotechnol
– volume: 19
  start-page: 207
  year: 2003
  ident: 155_CR32
  publication-title: Annu Rev Cell Dev Biol
  doi: 10.1146/annurev.cellbio.19.011102.111135
SSID ssj0021545
Score 2.427635
Snippet Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of...
Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the...
Abstract Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 26
SubjectTerms Apoptosis
Bone cancer
Cell cycle
Cell growth
ceRNA
Epigenetics
Gene expression
HMGB1
HULC
Liver cancer
Metastasis
MicroRNAs
miR-372-3p
Osteosarcoma
Proteins
Sarcoma
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SEHwRvz2tEsE3Cd0km2Tz2BbrIW0figd9WyZfeGB3S-8K9r93kuwdPRF98WFfkglkM5Od37AzvyHkoxSNDZwn5kSUrJUGmLWgGHpuDtp1nRW5dvjsXM8X7ddLdXmv1VfOCav0wPXgDrg3KYomBPR1LUQJ2kKSqY3eOA2hQCP0eZtgagq1MjCo2YaaZVCwKZfpdC6ayyFTeTJgYGrHJRXm_j_Bzd-zJu-5oZMn5PGEH-lh3fdT8iAOz8jD2lHy7jlJp4O_OD-k88XpMcVwGxW3oojxaMnDqhwcdEw0l3aMKzTy8Qqou6M3tSU9-rEifbW8wG-CYPL6YH725YjTnOYBhb6bws_l6gVZnHz-djxnUysF5jFiWDMrnOAQusitTYYnrwJYk5R0VnqcNF6CjAFHwUXTBK2jUDGAd4gfGt_Il2RvGIf4mlDg0SYVBcgmthjcgUyRt5BJZhSooGaEb06z9xPPeG538aMv8Uan-6qBvjxZAz2u-bRdc11ZNv4qfZSVtJXMDNllAO2mn-ym_5fdzMj-RsX9dG1XfW4OYKWV2szIh-00Xrj8FwWGON6ijDQ2t8ZoxYy8qhax3YlEwIQRM642O7ays9XdmWH5vZB6G8Rmyoo3_-Pd3pJHoti3ZLzbJ3vrm9v4DrHT2r0v1-QXuyUU_Q
  priority: 102
  providerName: Directory of Open Access Journals
Title LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis
URI https://www.ncbi.nlm.nih.gov/pubmed/32188407
https://www.proquest.com/docview/2546939367
https://www.proquest.com/docview/2379031542
https://pubmed.ncbi.nlm.nih.gov/PMC7081592
https://doaj.org/article/1c7fe20dd0744ae3a69af3f4ec7b6ada
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBZtQqGX0nfdpkaF3orISlqtVqcShySmJKaYGnxbZvVoDc2uazvQ_PuOtGunLiUH7UEPEDsj6Rtp5htCPkqRGcd5YLXwkuVSAzMGFMOTm0NRl6URMXb4alKMZ_mXuZr3F27r3q1yuyemjdq1Nt6RH0fediONLPTn5S8Ws0bF19U-hcZDchipy6JLl57fGVwRHnQ-hwWL0GAbNFMWMXQuGk6pRNjA1N7BlPj7_wc6__Wd_OswOn9KnvQokp50Yn9GHvjmOXnU5ZW8fUHCZWOnkxM6nl2eUjS6UXxrikiPJm-sjomDtoHGAI92jareXgOtb-mqS0yPp1nqfb2Y4s4gmFwej68uRpxGZw9IJN4Ufi_WL8ns_Ozb6Zj1CRWYRbthw4yoBQdXem5M0DxY5cDooGRtpMVGbSVI77AWaq8zVxReKO_A1ogiMpvJV-SgaRv_hlDg3gTlBcjM52jigQye5xCpZhQopwaEb_9mZXu28Zj04meVrI6yqDoJVKlECVQ45tNuzLLj2ri39ygKadcz8mSninb1veqXXcWtDl5kziFSysFLKAwEGXJvdV2AgwE52oq46hfvurpTtQH5sGvGZRffUqDx7Q32kdrEBBm5GJDXnUbsZiIRNqHdjKP1nq7sTXW_pVn8SNTeGhGaMuLt_dN6Rx6LpLmS8fKIHGxWN_49YqNNPUwLYEgOR2eTr9NhumHA78Wc_wG_nQ4y
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLdGJwQXxDeFAUaCE7IW20kcHxBax0bH2gpVq7RbcPxRKrGktJ2g_xR_I89OUihCu-3gi_0cWX7v2b8Xvw-EXnMWSUOpIwWznMRcKCKlSgjc3FSlRZZJ5mOHh6O0P4k_nSfnO-hXGwvj3SrbMzEc1KbS_h_5vs_bLrnkqXg__0581Sj_utqW0KjF4tSuf4DJtnx38gH4-4ax46Ozwz5pqgoQDeB5RSQrGFUms1RKJ6jTiVFSuIQXkmsYFJorbg30qsKKyKSpZYk1ShdwlUY64vDdG2g35mDKdNBu72j0ebwx8Twgqb0cU-LBSBumk6U-WM-baqF5oEKSraswVAz4H8z911vzr-vv-C660-BWfFAL2j20Y8v76GZdyXL9ALlBqcejA9yfDA4xmPkgMEsM2BIH_6869weuHPYhJdUSdrG6ULhY44Wdhvph5TRQX8zGcBYxwuf7_eHHHsXevUSFtOFY_ZwtH6LJtWz2I9Qpq9I-QVhRK11imeKRjcGoVNxZGiuf3CZRiUm6iLa7mesmv7kvs_EtD3ZOluY1B_LQPAdymPN2M2deZ_e4krrnmbSh9Jm5Q0e1mOaNoudUC2dZZAxgs1hZrlKpHHex1aJIlVFdtNeyOG-Oi2X-R7i76NVmGBTdv96o0laXQMOF9CU5YtZFj2uJ2KyEA1ADSx1miy1Z2Vrq9kg5-xqSiQvAhIlkT69e1kt0q382HOSDk9HpM3SbBSnmhGZ7qLNaXNrngMxWxYtGHTD6ct0a-Btzo0rx
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLfGEIgL4pvCACPBCVmN7TiODwjtg9KxrkITlXrLnNgulbakaztB_zX-Op6dpKMI7baDL_ZzZPm9Z_9e_D4QesdZpAyljuTMchJzqYlSWhC4ualO8jRVzMcOHw-T_ij-OhbjLfS7jYXxbpXtmRgOalMV_h951-dtV1zxRHZd4xbx7aD3aXZBfAUp_9LaltOoReTIrn6C-bb4eHgAvH7PWO_z9_0-aSoMkAKA9JIoljOqTWqpUk5SVwijlXSC54oXMCgLrrk10KtzKyOTJJYJa3SRw7UaFRGH795CtyUX1OuYHF8Zex6a1P6OCfGwpA3YSRMftueNttA8ZCFi41IMtQP-B3j_9dv86yLsPUD3GwSLd2uRe4i2bPkI3alrWq4eIzcoi5PhLu6PBvsYDH4QnQUGlImDJ1idBQRXDvvgkmoBe1ida5yv8NxOQiWxchKoz6cncCoxwmfd_vGXPYq9o4kOCcSx_jVdPEGjG9nqp2i7rEr7HGFNrXLCMs0jG4N5qbmzNNY-zY3QwogOou1uZkWT6dwX3DjLgsWTJlnNgSw0z4EM5nxYz5nVeT6upd7zTFpT-hzdoaOaT7JG5TNaSGdZZAygtFhbrhOlHXexLWSeaKM7aKdlcdYcHIvsSsw76O16GFTev-Po0laXQMOl8sU5YtZBz2qJWK-EA2QDmx1myw1Z2Vjq5kg5_RHSiktAh0KxF9cv6w26C3qXDQ6HRy_RPRaEmBOa7qDt5fzSvgKItsxfB13A6PSmle8PMa1NwQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LncRNA+HULC+induces+the+progression+of+osteosarcoma+by+regulating+the+miR-372-3p%2FHMGB1+signalling+axis&rft.jtitle=Molecular+medicine+%28Cambridge%2C+Mass.%29&rft.au=Li%2C+Yong&rft.au=Liu%2C+Jing-Jing&rft.au=Zhou%2C+Jia-Hui&rft.au=Chen%2C+Rui&rft.date=2020-03-18&rft.issn=1076-1551&rft.eissn=1528-3658&rft.volume=26&rft.issue=1&rft_id=info:doi/10.1186%2Fs10020-020-00155-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s10020_020_00155_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-1551&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-1551&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-1551&client=summon